A technique for systemic mesenchymal stem cell transplantation in newborn rat pups

Journal of Investigative Surgery

Volumn 25, Issue 6, 2012, Pages 405-414

  Yang, Jixin ^a   Watkins, Daniel ^a   Chen, Chun Liang ^a   Zhang, Hong Yi ^a   Zhou, Yu ^a   Velten, Markus ^a   Besner, Gail E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Cell transplantation; Intravenous; Mesenchymal stem cells; Newborn; Rat model; Umbilical vein

Indexed keywords

METHYLENE BLUE; VIMENTIN; YELLOW FLUORESCENT PROTEIN;

ADULTHOOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANNULATION; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MORTALITY; MOUSE; MULTIPOTENT STEM CELL; NEWBORN; NEWBORN PERIOD; NONHUMAN; OPERATION DURATION; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SAFETY; SPRAGUE DAWLEY RAT; SYSTEMIC THERAPY; TISSUE INJURY; TISSUE REGENERATION; UMBILICAL VEIN;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; FEMALE; INJECTIONS, INTRAVENOUS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MODELS, ANIMAL; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; UMBILICAL VEINS;

EID: 84866355018     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2012.661519     Document Type: Article

References (31)

1. Hwang NS, Zhang C, Hwang YS, et al. Mesenchymal stem cell differentiation and roles in regenerative medicine. Wiley Interdiscip Rev Syst Biol Med. 2009;1:97-106.
2. Arnhold S, Heiduschka P, Klein H, et al. Adenovirally transduced bone marrow stromal cells differentiate into pigment epithelial cells and induce rescue effects in RCS rats. Invest Ophthalmol Vis Sci. 2006;47:4121-4129.
3. Oswald J, Boxberger S, Jorgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22:377-384.
4. Hocking AM, Gibran NS. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Exp Cell Res. 2010;316:2213-2219.
5. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hM-SCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-infammatory protein TSG-6. Cell Stem Cell. 2009;5:54-63.
6. Liotta F, Angeli R, Cosmi L, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mes-enchymal stem cells and can inhibit their T-cell modu-latory activity by impairing Notch signaling. Stem Cells. 2008;26:279-289.
7. Dimmeler S, Burchfeld J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008;28:208-216.
8. Ott HC, McCue J, Taylor DA. Cell-based cardiovascular repair-The hurdles and the opportunities. Basic Res Cardiol. 2005;100:504-517.
9. Sherman W, Martens TP, Viles-Gonzalez JF, et al. Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med. 2006;3 (Suppl 1):S57-S64.
10. Abdel-Mageed AS, Senagore AJ, Pietryga DW, et al. Intravenous administration of mesenchymal stem cells genetically modifed with extracellular superoxide dis-mutase improves survival in irradiated mice. Blood. 2009;113:1201-1203.
11. Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995;16:557-564.
12. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Trans-plantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309-313.
13. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-1586.
14. Wu KH, Chan CK, Tsai C, et al. Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Tr a n s p l a n-tation. 2011;91:1412-1416.
15. Schrepfer S, Deuse T, Reichenspurner H, et al. Stem cell transplantation: the lung barrier. Transplant Proc. 2007;39:573-576.
16. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary frst-pass effect. Stem Cells Dev. 2009;18:683-692.
17. Ramot Y, Steiner M, Morad V, et al. Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. Nanotoxicology. 2010;4:98-105.
18. Furlani D, Ugurlucan M, Ong L, et al. Is the intravascu-lar administration of mesenchymal stem cells safe? Mes-enchymal stem cells and intravital microscopy. Microvasc Res. 2009;77:370-376.
19. Hall B, Andreeff M, Marini F. The participation of mes-enchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol. 2007;180:263-283.
20. Nanbo T. A method to inject the umbilical vein of the rat. Reprod Toxicol. 1990;4:203-208.
21. Nasu T, Arishima K. Development of the ductus veno-sus in the SD rat. Fukuoka Igaku Zasshi. 2004;95:9-16.
22. Ozer EA, YilmazO, AkhisaroquM, etal. Heat shock protein 70 expression in neonatal rats after hypoxic stress. J Matern Fetal Neonatal Med. 2002;12:112-117.
23. Pillai SB, Luquette MH, Nowicki PT, et al. Segmental intestinal ischemia: an improved method of producing small bowel injury. J Invest Surg. 1998;11:123-128.
24. Xia G, Rachfal AW, Martin AE, et al. Upregulation of endogenous heparin-binding EGF-like growth factor (HB-EGF) expression after intestinal ischemia/reperfusion injury. J Invest Surg. 2003;16:57-63.
25. Graham ML, Mutch LA, Rieke EF, et al. Long-term heptic vascular access in the nonhuman primate for recurrent portal vein infusion. J Invest Surg. 2011;24:59-66.
26. Kliegman RM, Fanaroff AA. Necrotizing enterocolitis. N Engl J Med. 1984;310:1093-1103.
27. Yu X, Radulescu A, Zorko N, et al. Heparin-binding EGF-like growth factor increases intestinal microvascular blood fow in necrotizing enterocolitis. Gastroenterology. 2009;137:221-230.
28. Feng J, El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor decreases the incidence of necrotizing enterocolitis in neonatal rats. J Pediatr Surg. 2006;41:144-149; discussion 144-149.
29. Feng J, El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor reduces intestinal apoptosis in neonatal rats with necro-tizing enterocolitis. J Pediatr Surg. 2006;41:742-747; discussion 742-747.
30. Feng J, Besner GE. Heparin-binding epidermal growth factor-like growth factor promotes enterocyte migration and proliferation in neonatal rats with necrotizing entero-colitis. J Pediatr Surg. 2007;42:214-220.
31. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med. 2010;16:203-209.